An experimental vaccine for Ebola from GlaxoSmithKline will be tested in humans in the Clinical Center Bethesda (Maryland), on the outskirts of Washington next week.
“We got the green light to start,” said Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), a department of the National Institute of Health (NIH).
The company plans to produce up to 10,000 stock doses for an emergency deployment if the results are positive.
Tests will be conducted at 20 healthy adult volunteers, to which the vaccine will be injected in the arm in order to check if it is safe and if it generates the immune response it should to protect the body from Ebola.
The vaccine would also be provided to healthy volunteers in Britain and the United States since mid-September and then, the program will be extended to Gambia and Mali.